Kiniksa Pharmaceuticals, Ltd.
NASDAQ:KNSABiotechnology
+$0.42 today
- Market cap
- $7.47B
- Beta
- 0.12
- P/E (TTM)
- 57.2
- EPS (TTM)
- $0.95
Volume 0.33M
Average 0.66M
KNSA Operating Margin
Operating income as a percentage of revenue, showing the profitability of core operations.
Kiniksa Pharmaceuticals, Ltd.NASDAQ: KNSA
Operating Margin · Q2 FY2026 · quarter ended Jun 2026
Operating margin narrows to 11.2%
Operating margin was 11.2% in Q2 FY2026, down 1.7 pp from a year earlier. On a trailing-twelve-month basis it was 11.9%, up 11.1 pp year over year. Over 3 fiscal years it widened by 7.0 pp.
Context
- Operating margin widened in 1 of the last 3 fiscal years.
- FY2025 was the highest level in the 4 fiscal years shown.
What to watch
Whether operating margin reaches the consensus estimate from 5 analysts of 15.1% for the fiscal year ending Dec 2026, up from 11.4% in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterJun 2026
- 11.2%-2.5 pp QoQ
- Last fiscal yearDec 2025
- 11.4%+22.2 pp YoY
- LTMJun 2026
- 11.9%+11.1 pp YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -1.7 pp | +3.2 pp | +4.9 pp |
| 1 year | +22.2 pp | +3.7 pp | -18.4 pp |
| 3 years | +7.0 pp | +5.2 pp | -1.8 pp |
| 5 years | +27.5 pp | — | |
| 10 years | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Operating Margin history
Percent of revenue · from the income statement
- Latest · FY2025
- 11.4%
- Year-over-year change
- +22.2pp
| Period | Period end | Operating Margin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 11.4% | +22.2pp |
| FY2024 | 2024-12-31 | -10.8% | -1.5pp |
| FY2023 | 2023-12-31 | -9.3% | -13.8pp |
| FY2022 | 2022-12-31 | 4.4% | +410.8pp |
| FY2021 | 2021-12-31 | -406.4% | — |
Operating Margin vs competitors
How KNSA compares with its peers on the latest reported figures
- KNSA's LTM Jun 2026 operating margin of 11.9% is the 3rd highest of the 9 companies compared; the peer median is -619.2%.
- Its year-over-year change of +11.1 pp is the 3rd highest of 7, against a peer median of -81.1 pp.
- Over three fiscal years its change of +7.0 pp compares with a peer median of -338.6 pp.
| Company | Period | LTM level | YoY | 3-year change |
|---|---|---|---|---|
| LTM Aug 2026 | 41.3% | +360.6 pp | +135.8 pp | |
| LTM Mar 2026 | 17.6% | +107.2 pp | +1139.8 pp | |
| LTM Jun 2026 | 11.9% | +11.1 pp | +7.0 pp | |
| LTM Mar 2026 | 6.3% | +6.1 pp | -3.3 pp | |
| LTM Sep 2026 | -276.5% | — | — | |
| LTM Mar 2026 | -961.9% | -168.3 pp | -673.9 pp | |
| LTM Sep 2026 | -7488.4% | — | — | |
| LTM Jun 2026 | -11441.4% | -8764.8 pp | -8276.4 pp | |
| LTM Mar 2026 | -134164.4% | -122732.2 pp | -123394.3 pp | |
ORKAOruka Therapeutics, Inc. | FY2025 | — | — | — |
| Peer median (excluding KNSA) | -619.2% | -81.1 pp | -338.6 pp | |
Competitors are the stored peer set for KNSA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 38.54M | 220.18M | 270.26M | 423.24M | 677.56M |
| Cost of Revenue | 9.1M | 22.9M | 56.52M | 60.91M | 307.41M |
| Gross Profit | 29.44M | 197.29M | 213.74M | 362.33M | 370.15M |
| Gross Margin | 76.4% | 89.6% | 79.1% | 85.6% | 54.6% |
| Research & Development | 99.3M | 65.49M | 76.1M | 111.62M | 96.85M |
| Selling, General & Admin | 85.95M | 97.95M | 129.43M | 168.01M | 196.27M |
| Operating Expenses | 186.08M | 187.51M | 238.93M | 407.95M | 292.93M |
| Depreciation & Amortization | 2.36M | 2.4M | 2.34M | 1.7M | 1.55M |
| EBITDA | (154.18M) | 13.43M | (14.31M) | (34.46M) | 90.42M |
| EBITDA Margin | -400.0% | 6.1% | -5.3% | -8.1% | 13.3% |
| Operating Income | (156.64M) | 9.77M | (25.2M) | (45.62M) | 77.22M |
| Operating Margin | -406.4% | 4.4% | -9.3% | -10.8% | 11.4% |
| Interest Income | 97K | 1.25M | 8.54M | 9.46M | 11.65M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 97K | 1.25M | 8.54M | 9.46M | 11.65M |
| Income Before Tax | (156.54M) | 11.03M | (16.65M) | (36.15M) | 88.87M |
| Pre-Tax Margin | -406.1% | 5.0% | -6.2% | -8.5% | 13.1% |
| Income Tax Expense | 1.39M | (172.34M) | (30.74M) | 7.04M | 29.86M |
| Net Income | (157.92M) | 183.36M | 14.08M | (43.19M) | 59.01M |
| Net Margin | -409.7% | 83.3% | 5.2% | -10.2% | 8.7% |
| EPS (Basic) | (2.30) | 2.64 | 0.20 | (0.60) | 0.80 |
| EPS (Diluted) | (2.30) | 2.60 | 0.20 | (0.60) | 0.75 |
| Weighted Avg Shares | 68.58M | 69.38M | 70.06M | 71.42M | 74.2M |
| Weighted Avg Shares (Diluted) | 68.58M | 70.42M | 71.92M | 71.42M | 78.98M |
Kiniksa Pharmaceuticals, Ltd.
NASDAQ:KNSA
Intrinsic Alpha fair value
Locked
Current Price
$95.05
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.